Choose your country to see the products for your location
We have successfully obtained our certification under the new In Vitro Diagnostic Regulation (IVDR; 2017/746)! Very soon, the first batch of flagship products will be available on the market under the new IVDR, well in advance of the transition period deadline.
In the coming years we will update product descriptions for SALSA® MLPA® products that are for in vitro diagnostic (IVD) use to a new structure and layout.
Researchers from the University of Belgrade succeeded in making state-wide newborn screening become a reality through a stepwise plan that included a laboratory validation step, a feasibility study on a smaller cohort of newborns, and finally the transition to a national program.
Researchers from the Amsterdam University Medical Centre recently published a study on a distinct subclass of head and neck cancers in collaboration with MRC Holland scientists.
P105 Glioma just received a major update that enables a more complete characterization of the genetic landscape of gliomas. The recently released E1 version includes two probes specific for the common TERT C228T and C250T SNVs.
ME034 Multi-locus Imprinting just received a major update, with the recently released D1 version featuring several new and improved target and reference probes that expand the differentially methylated regions investigated and ensure an even more robust assay output.
D007 Acute Lymphoblastic Leukemia just received an update, with version B1 featuring new probes that increase the coverage of ALL-relevant regions and target genes of emerging interest for ALL.
Effective from 1 January 2025, we will be implementing a price increase of approximately 1.9% on most of our products.
MRC Holland will be closed from December 25, 2024 until January 2, 2025.
D001 Hereditary Cancer Panel 1 recently received an update, with version D1 featuring several new modified probes, increasing the performance and coverage of the product.
Join our mailing list to receive the latest information about our products, technologies and website.